Drug target · HTR2C
5-HT2C
5-hydroxytryptamine receptor 2C
9 compounds in the CNS pipeline act on 5-HT2C.
Compounds targeting 5-HT2C
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| Olanzapine extended-release injectable suspension (TEV-'749)Small molecule | Antagonist | — | Filed (NDA)Schizophrenia | Teva Pharmaceutical Industries Ltd. |
| Lysergide D-tartrate (MM120 / LSD)Psychedelic | Agonist | pKi 8.2 | Phase 3Generalized anxiety disorder | Definium Therapeutics, Inc. |
| Psilocybin (COMP360)Psychedelic | Agonist | pKi 6.85 | Phase 3Treatment-resistant depression | COMPASS Pathways plc |
| RemlifanserinSmall molecule | Inverse agonist | — | Phase 3Alzheimer's disease psychosis | ACADIA Pharmaceuticals Inc. |
| ALTO-300 (agomelatine)Small molecule | Antagonist | Ki 631 nM | Phase 2Major depressive disorder | Alto Neuroscience, Inc. |
| Bretisilocin (GM-2505)Psychedelic | Agonist | EC50 9.5 nM | Phase 2Major depressive disorder | Gilgamesh Pharmaceuticals, Inc. |
| VLS-01Psychedelic | Agonist | — | Phase 2Treatment-resistant depression | Atai Beckley N.V. (AtaiBeckley) |
| ELE-101 (intravenous psilocin benzoate)Psychedelic | Agonist | — | Phase 1/2Major depressive disorder | Beckley Psytech Limited |
| Zalsupindole (DLX-001)Small molecule | Partial agonist | — | Phase 1Major depressive disorder | Delix Therapeutics, Inc. |